MORPHIC HOLDING Reports Earnings Results for Q2 of Fiscal Year 2023

August 29, 2023

🌥️Earnings Overview

On August 3, 2023, MORPHIC HOLDING ($NASDAQ:MORF) revealed their financial results for the second quarter of fiscal year 2023 which ended on June 30, 2023. Their total revenue was USD 0.0 million, an enormous decrease of 100.0% compared to the same period in the previous year. Net income was reported at USD -39.0 million, a major decline from last year’s figure of USD 26.8 million.

Stock Price

The company‚Äôs stock opened the trading day at $55.7 and closed at $57.6, a drop of 1.9% from the previous closing price of $58.7. Their financials showed strong growth in revenue and income, and their balance sheet was healthy with increasing assets and equity. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Morphic Holding. More…

    Total Revenues Net Income Net Margin
    8.71 -129.55 -1487.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Morphic Holding. More…

    Operations Investing Financing
    -104.5 -255.27 435.87
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Morphic Holding. More…

    Total Assets Total Liabilities Book Value Per Share
    748.72 19.36 15.23
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Morphic Holding are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -22.4% -1636.8%
    FCF Margin ROE ROA
    -1212.9% -15.4% -11.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, our team of analysts have taken a thorough look at the fundamentals of MORPHIC HOLDING. We have come to the conclusion that, based on our Risk Rating system, MORPHIC HOLDING is a medium risk investment in terms of financial and business aspects. It is important to note that our Risk Rating system is not a guarantee of success or failure, but simply indicates the level of risk associated with this investment. Furthermore, our analysts have detected three risk warnings in the balance sheet, cashflow statement, and financial journal. These warnings indicate potential issues, which should be taken into consideration before investing. If you would like to learn more about these warnings and what steps you can take to mitigate them, register with us and we can provide detailed information. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    As a leader in the biopharmaceutical industry, Morphic Holding Inc is competing against several other companies in the same space, such as Kinarus Therapeutics Holding AG, Oncotelic Therapeutics Inc, and Phathom Pharmaceuticals Inc. All of these companies are striving to develop innovative treatments and are committed to improving the lives of people affected by serious illnesses.

    – Kinarus Therapeutics Holding AG ($LTS:0QNS)

    Kanarus Therapeutics Holding AG is a biopharmaceutical company that specializes in the development of novel treatments for rare, serious, and life-threatening immune-mediated diseases. The company’s market cap is currently 12.62M as of 2022 and its Return on Equity is 41.67%. This indicates that the company is performing well financially and is able to generate a healthy return for its investors. The company is well-positioned to continue to grow, as it focuses its efforts on developing innovative therapies for rare diseases.

    – Oncotelic Therapeutics Inc ($OTCPK:OTLC)

    Oncotelic Therapeutics Inc is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies. As of 2022, Oncotelic Therapeutics Inc has a market cap of 18.58M and a Return on Equity of 27.43%, which is indicative of its financial performance and potential as a company. Market capitalization is the estimated value of a company and is calculated by multiplying the current stock price by the total number of shares outstanding, while Return on Equity (ROE) measures how well the company utilizes its investments to generate profits. Oncotelic Therapeutics Inc has been able to generate a high ROE indicating that the company is using its resources efficiently to generate profits for its shareholders.

    – Phathom Pharmaceuticals Inc ($NASDAQ:PHAT)

    Phathom Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing treatments for serious medical conditions. With a market cap of 469.9M as of 2022, the company has been able to achieve strong financial performance and deliver strong returns for its investors. The company’s Return on Equity (ROE) of 591.0% is an impressive figure that indicates the company’s strong profitability and efficient use of capital. Phathom Pharmaceuticals Inc is poised to continue to experience strong growth and profitability in the coming years, making it an attractive investment opportunity for investors.

    Summary

    MORPHIC HOLDING reported dismal Q2 earnings results for FY2023, with total revenue plummeting 100.0% year-over-year to USD 0.0 million. Net income was a loss of USD -39.0 million, compared to a profit of USD 26.8 million in the prior year. Investors should be aware that this could indicate a wider economic downturn and should be wary of investing in MORPHIC HOLDING at this time. It is important to evaluate the long-term prospects of the company and their ability to recover from such a large financial loss before committing to an investment.

    Recent Posts

    Leave a Comment